METHODS FOR REMOVING CYTOKINES FROM BLOOD WITH SURFACE IMMOBILIZED POLYSACCHARIDES

• US 20180361050A1
• Filed: 08/27/2018
• Published: 12/20/2018
• Est. Priority Date: 12/01/2009
• Status: Active Grant

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: WARD, ROBERT S., McCREA, Keith R., LARM, Olle, ADOLFSSON, Lars
• Granted Patent: US 11,123,466 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/722 Chitin, chitosan
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 1/3496 Plasmapheresis; Leucopheresis; Lymphopheresis A61M1/3472 takes precedence
• CPC Class Codes: A61M 1/36 Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
• CPC Class Codes: A61M 1/362 changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
• CPC Class Codes: A61M 1/3621 Extra-corporeal blood circuits single-needle circuits A61M1/30
• CPC Class Codes: A61M 1/3673 Anticoagulant coating, e.g. Heparin coating
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 1/3687 Chemical treatment A61M1/3675 takes precedence
• CPC Class Codes: A61M 1/38 Removing constituents from donor blood and storing or returning remainder to body , e.g. for transfusion
• CPC Class Codes: A61M 2202/0057 retained by adsorption
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Claims

1. A device for removing an adsorbate selected from cytokines, pathogens and toxins from blood, the device comprising:

a container which comprises a solid substrate of high surface area having at least one polysaccharide adsorbent on the surface thereof with a binding affinity for the adsorbate, wherein the at least one polysaccharide comprises a carbohydrate with mannose sequences; and

wherein the solid substrate has interstitial channel spaces large enough to permit the transport of blood cells, and during blood flow the adsorbate binds to binding sites on the at least one polysaccharide adsorbent becoming separated from the blood and the transport of the adsorbates from blood to adsorbent sites on the solid substrate is primarily by convection transport.

2. The device of claim 1, wherein the solid substrate is a member selected from the group consisting of beads, fibers, reticulated foams, and spiral-wound dense membranes.

3. The device of claim 2, wherein the solid substrate is comprises a plurality of rigid polymer beads.

4. The device of claim 3, wherein the rigid polymer beads are rigid polyethylene beads.

5. The device of claim 4, wherein the beads have a diameter ranging from 100 to 450 microns.

6. The device of claim 5, wherein the beads have an average diameter of 0.3 mm.

7. The device of claim 1, wherein the at least one polysaccharide further comprises a member selected from the group consisting of heparin, heparan sulfate, hyaluronic acid, sialic acid, and chitosan.

8. The device of claim 2, wherein the beads are coated with 0.5-10 mg heparin per gram of bead.

9. The device of claim 8, wherein the heparin has a mean molecular weight of about 8 kDa.

10. The device of claim 8, wherein the heparin is attached to the substrate by covalent end-point attachment.

11. The device of claim 1, wherein the at least one polysaccharide with mannose sequences is end-point attached.

12. The device of claim 10, wherein the container further comprises a solid substrate having on the surface thereof a cationic, positively charged molecule having an affinity for the cytokine, pathogen or toxin, but being more thrombogenic than heparin.

13. The device of claim 12, wherein the cationic, positively charged molecule is chitosan or polyethylene imine.

14. A method for removing an adsorbate selected from cytokines, pathogens and toxins from blood, the method comprising:

contacting blood with a device having a solid substrate of high surface area with at least one polysaccharide adsorbent on the surface thereof with a binding affinity for the adsorbate, wherein the at least one polysaccharide adsorbent comprises a carbohydrate with mannose sequences; and

wherein the solid substrate has interstitial channel spaces large enough to permit the transport of blood cells, and during blood flow the adsorbate binds to binding sites on the at least one polysaccharide adsorbent, becoming separated from the blood and wherein the transport of the adsorbates from blood to adsorbent sites on the solid substrate is primarily by convection transport, to thereby remove the adsorbate.

15. The method of claim 14, wherein the solid substrate is a member selected from the group consisting of beads, fibers, reticulated foams, and spiral-wound dense membranes.

16. The method of claim 15, wherein the solid substrate comprises a plurality of rigid polymer beads.

17. The method of claim 14, wherein the linear flow velocity of blood flowing through the device is between about 8 and 24 cm/minute.

18. The method of claim 14, wherein the at least one polysaccharide with mannose sequences is end-point attached.

19. The method of claim 14, wherein the device further comprises a solid substrate having on the surface thereof a cationic, positively charged molecule having an affinity for the cytokine, pathogen or toxin, but being more thrombogenic than heparin.

20. The method to claim 14, wherein the cytokine is selected from the group consisting of IL-6, VCAM, TNF-α

, GRO-α

, IL-8, and RANTES.